TheraRadar
Landscape → Metabolic

NASH/NAFLD Clinical Trial Landscape

Data updated: May 20, 2026

676 clinical trials tracked since 2008

Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD) are conditions characterized by fat buildup in the liver, often affecting individuals with metabolic disorders. The clinical trial landscape for NASH/NAFLD is active, with 673 trials registered since 2008, including 115 currently active studies. The majority of ongoing research is concentrated in Phase 2 trials, with 61 active studies, compared to 21 in Phase 3 and 19 in Phase 4. Phase 1 trials account for 20 of the active studies. Industry sponsorship is led by GSK, which currently has 5 active trials. Akero Therapeutics, Inc. follows with 4 active trials, while Madrigal Pharmaceuticals, Inc. has 3. Novo Nordisk and Corcept Therapeutics are also active sponsors in this space, each with 2 ongoing trials. The high proportion of Phase 2 trials suggests a strong focus on evaluating novel therapeutic approaches in mid-stage development.

115 active
/
676 total (since 2008)
20
Phase 1 Active
174 total
59
Phase 2 Active
356 total
22
Phase 3 Active
105 total
19
Phase 4 Active
97 total

Top Industry Sponsors

Sorted by active Active Done Failed
GSK 5 1 1
Akero Therapeutics, Inc 4 2 0
Corcept Therapeutics 3 3 1
Madrigal Pharmaceuticals, Inc. 3 3 0
Novo Nordisk 2 9 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT03900429 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals, Inc. n=1,759
NCT06884293 ACTIVE NOT RECRUITING
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Innovent Biologics (Suzhou) Co. Ltd. n=479
NCT06419374 RECRUITING
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
89bio, Inc. n=762
NCT06318169 RECRUITING
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
89bio, Inc. n=1,350
NCT06161571 ACTIVE NOT RECRUITING
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Akero Therapeutics, Inc n=700

+ 100 more Phase 3 trials — see full database below

NASH/NAFLD — Trials Started by Year (last 10 years)

2016
36
2017
36
2018
41
2019
54
2020
48
2021
56
2022
42
2023
62
2024
35
2025
26
2026
11

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

GSK
7
Akero Therapeutics, Inc
6
Corcept Therapeutics
7
Madrigal Pharmaceuticals, Inc.
6
Novo Nordisk
11
89bio, Inc.
5
Merck
7
Gannex Pharma Co., Ltd.
5
Sinew Pharma Inc.
4
Rivus Pharmaceuticals, Inc.
4

Active Trials by Phase

Phase 1
20
Phase 2
59
Phase 3
22
Phase 4
19

Enrollment Size Distribution

1-50
251
51-200
311
201-500
61
501-1k
13
1k+
15

All Industry Sponsors

Sorted by active Active Done Failed
GSK 5 1 1
Akero Therapeutics, Inc 4 2 0
Corcept Therapeutics 3 3 1
Madrigal Pharmaceuticals, Inc. 3 3 0
Novo Nordisk 2 9 0
89bio, Inc. 2 3 0
Merck 1 5 1
Gannex Pharma Co., Ltd. 1 3 1
Sinew Pharma Inc. 1 2 1
Rivus Pharmaceuticals, Inc. 1 3 0
Inventiva Pharma 1 2 0
Hanmi Pharmaceutical Company Limited 1 1 1
Guangdong Raynovent Biotech Co., Ltd 1 2 0
Hepion Pharmaceuticals, Inc. 1 2 0
Haisco Pharmaceutical Group Co., Ltd. 1 1 0
NCT03900429 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals, Inc. n=1,759
NCT07581951 NOT YET RECRUITING
A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASH
Haisco Pharmaceutical Group Co., Ltd. n=400
NCT06884293 ACTIVE NOT RECRUITING
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Innovent Biologics (Suzhou) Co. Ltd. n=479
NCT06419374 RECRUITING
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
89bio, Inc. n=762
NCT06318169 RECRUITING
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
89bio, Inc. n=1,350
NCT06161571 ACTIVE NOT RECRUITING
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Akero Therapeutics, Inc n=700
NCT06528314 RECRUITING
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc n=2,150
NCT04822181 ACTIVE NOT RECRUITING
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Novo Nordisk A/S n=1,205
NCT06215716 RECRUITING
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc n=1,650
NCT07221227 RECRUITING
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
GlaxoSmithKline n=1,200
NCT07221188 RECRUITING
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
GlaxoSmithKline n=1,250
NCT04849728 ACTIVE NOT RECRUITING
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Inventiva Pharma n=1,000
NCT07219602 RECRUITING
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma n=300
NCT05935826 RECRUITING
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
University of Colorado, Denver n=55
NCT07065357 ENROLLING BY INVITATION
Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor
The University of Hong Kong n=160
NCT04833140 RECRUITING
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Massachusetts General Hospital n=60
NCT04951219 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals, Inc. n=1,000
NCT06908473 ENROLLING BY INVITATION
Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients
Guangdong Provincial Hospital of Traditional Chinese Medicine n=530
NCT05500222 ACTIVE NOT RECRUITING
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Madrigal Pharmaceuticals, Inc. n=700
NCT05073835 ACTIVE NOT RECRUITING
Semaglutide 2.4 mg in Patients With Poor Weight-loss
University College, London n=70
NCT05905965 RECRUITING
Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
Collegium Medicum w Bydgoszczy n=200
NCT06152991 ENROLLING BY INVITATION
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
Yoon Jun Kim n=196
NCT06309992 COMPLETED
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
Boehringer Ingelheim n=218
NCT04365868 TERMINATED
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Galectin Therapeutics Inc. n=357
NCT04104321 SUSPENDED
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
Galmed Research and Development, Ltd. n=157
NCT03919929 COMPLETED
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
University of Colorado, Denver n=60
NCT03355469 COMPLETED
Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome
Rutgers University n=91
NCT06594523 WITHDRAWN
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Sagimet Biosciences Inc.
NCT06692283 WITHDRAWN
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
Sagimet Biosciences Inc.
NCT03031821 TERMINATED
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Canadian Urologic Oncology Group n=168
NCT02548351 TERMINATED
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
Intercept Pharmaceuticals n=2,477
NCT05284448 COMPLETED
Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis
Al-Azhar University n=50
NCT06348706 COMPLETED
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
Ain Shams University n=60
NCT03723252 COMPLETED
Dapagliflozin Efficacy and Action in NASH
Nanfang Hospital, Southern Medical University n=154
NCT02541045 WITHDRAWN
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
Hospital General de Mexico
NCT04237116 TERMINATED
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
Novartis Pharmaceuticals n=10
NCT05768334 COMPLETED
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
Helwan University n=116
NCT03439254 COMPLETED
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Intercept Pharmaceuticals n=919
NCT04197479 COMPLETED
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Madrigal Pharmaceuticals, Inc. n=1,343
NCT05457530 WITHDRAWN
Doravirine and Weight Gain in Antiretroviral Naive
Prism Health North Texas
NCT03633630 COMPLETED
Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
University of Guadalajara n=28
NCT04142749 COMPLETED
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis
PharmaKing n=146
NCT05521633 COMPLETED
Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver
King Edward Medical University n=96
NCT02704403 TERMINATED
Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Genfit n=2,157
NCT03028740 TERMINATED
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
Tobira Therapeutics, Inc. n=1,778
NCT02960711 COMPLETED
Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano n=1,600
NCT01529268 COMPLETED
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) n=169
NCT02983188 COMPLETED
Berberine as Adjuvant Treatment for Schizophrenia Patients
The University of Hong Kong n=113
NCT02113241 COMPLETED
Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
University of Guadalajara n=24
NCT03585413 COMPLETED
Impact of a Specific Micronutrient-probiotic-supplement on Fatty Liver of Patients After Mini-Gastric Bypass Surgery
Bonn Education Association for Dietetics r.A., Cologne, Germany n=60
NCT02183935 COMPLETED
Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner
University Medical Centre Ljubljana n=22
NCT03053050 TERMINATED
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Gilead Sciences n=808
NCT04411862 COMPLETED
Efficacy of Phosphatidylcholine in NAFLD
Nehal Abou Seada n=100
NCT03053063 TERMINATED
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences n=883
NCT02991209 COMPLETED
Study of Testosterone vs Placebo in Testicular Cancer Survivors
Mikkel Bandak n=69
NCT01234649 COMPLETED
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Woman's n=153
NCT00891267 COMPLETED
Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company n=60
NCT00676845 COMPLETED
Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company n=133
NCT00678587 TERMINATED
Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures
GlaxoSmithKline n=292
NCT03490097 COMPLETED
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
Ain Shams University n=100
NCT01465620 COMPLETED
Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study
Henri Mondor University Hospital n=8
NCT02842567 COMPLETED
Hydroxytyrosol and Vitamin E in Pediatric NASH
Bambino Gesù Hospital and Research Institute n=80
NCT02242149 COMPLETED
Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
Universidade Federal do Rio de Janeiro n=84
NCT02303314 COMPLETED
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
Shiraz University of Medical Sciences n=35
NCT02764957 COMPLETED
Green Coffee Extract and Metabolic Syndrome
National Nutrition and Food Technology Institute n=43
NCT02672592 COMPLETED
Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome
University Hospital, Basel, Switzerland n=70
NCT02216552 COMPLETED
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
University of Manitoba n=10
NCT01758601 COMPLETED
White Fish for Cardiovascular Risk Factors in Patients With Metabolic Syndrome: the WISH-CARE Study
Hospital Universitario Ramon y Cajal n=273
NCT02132442 COMPLETED
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
University of Massachusetts, Worcester n=12
NCT00916175 COMPLETED
Metabolic Syndrome and Functional Food
Universidad Autonoma de Nuevo Leon n=125
NCT01585493 COMPLETED
CHANGE -it is About Life
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital n=428
NCT01872182 TERMINATED
Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome
Hanmi Pharmaceutical Company Limited n=200
NCT02227420 COMPLETED
Effects of IL-1 Beta on the HPA-axis in Obese Persons
University Hospital, Basel, Switzerland n=76
NCT02778776 COMPLETED
Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome
Centro Universitario de Ciencias de la Salud, Mexico n=40
NCT02773927 COMPLETED
Combination of Metformin/Inulin vs Inulin on Adiponectin in Metabolic Syndrome
Centro Universitario de Ciencias de la Salud, Mexico n=40
NCT01849068 COMPLETED
Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study
Laval University n=20
NCT02068339 COMPLETED
Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis
PharmaKing n=283
NCT01754714 COMPLETED
Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
Abbott n=108
NCT02098317 COMPLETED
DHA and Vitamin D in Children With Biopsy-proven NAFLD
Bambino Gesù Hospital and Research Institute n=66
NCT01934777 COMPLETED
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
Bambino Gesù Hospital and Research Institute n=60
NCT01847807 COMPLETED
The Organ Protection of Astragalus in Subjects With Metabolic Syndrome
LanZhou University n=210
NCT01051219 COMPLETED
Anti-Fibrotic Effects of Losartan In Nash Evaluation Study
Newcastle-upon-Tyne Hospitals NHS Trust n=45
NCT02535195 COMPLETED
Effect of Ginger Supplement on Non-alcoholic Fatty Liver
Dr Azita Hekmatdoost n=60
NCT02497352 COMPLETED
Effects of Flaxseed Supplementation in Metabolic Syndrome
National Nutrition and Food Technology Institute n=44
NCT01794429 COMPLETED
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
Bjorn H. Ebdrup n=45
NCT00663104 TERMINATED
Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause
University of Erlangen-Nürnberg Medical School n=126
NCT00800033 COMPLETED
Effectiveness of Pulse-Based Foods Combined With Exercise for Improving Components of the Metabolic Syndrome
University of Saskatchewan n=87
NCT02189005 COMPLETED
Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels
Joe Fenn n=210
NCT02407522 COMPLETED
The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome
Sun Yat-sen University n=101
NCT01811511 COMPLETED
Efficacy and Safety of Chungkookjang on Improvement of Metabolic Syndrome
Chonbuk National University Hospital n=120
NCT00742742 COMPLETED
Walnut Intervention on Metabolic Syndrome (WIMS)
Chinese Academy of Sciences n=189
NCT00733772 COMPLETED
Flaxseed Intervention on Metabolic Syndrome
Chinese Academy of Sciences n=189
NCT01598233 COMPLETED
Effects of Intragastric Balloon on Bone, Metabolic and Respiratory Parameters
Universidade Federal do Rio de Janeiro n=50
NCT01418027 COMPLETED
Combined Intensive and Conventional Exercise on Nonalcoholic Fatty Liver Disease (NAFLD)
Shanghai Jiao Tong University School of Medicine n=220
NCT00783445 COMPLETED
Evaluating the Effectiveness of a Community Exercise Program to Reduce the Risk of Metabolic Syndrome Among Black Americans
Johns Hopkins University n=204
NCT01277237 COMPLETED
The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease
University of Edinburgh n=50
NCT02008838 COMPLETED
Effects of Synbiotic Supplementation in Metabolic Syndrome
National Nutrition and Food Technology Institute n=38
NCT00857818 TERMINATED
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
Otsuka Pharmaceutical Development & Commercialization, Inc. n=64
NCT01463748 COMPLETED
Effects of Graptopetalum Paraguayense E. Walther on the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome
Chung Shan Medical University n=54
NCT01319344 COMPLETED
Effect of Eplerenone on Endothelial Function in Metabolic Syndrome
University of Erlangen-Nürnberg Medical School n=42
NCT01664650 COMPLETED
Effects of Genistein in Postmenopausal Women With Metabolic Syndrome
University of Messina n=120
NCT00826774 COMPLETED
Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial)
University of Pennsylvania n=390
NCT00820651 COMPLETED
Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis
Catalysis SL n=158
NCT01022411 COMPLETED
Brown Rice Intervention on Metabolic Syndrome (BRIMS)
Chinese Academy of Sciences n=202
NCT01025115 COMPLETED
Diamel in the Treatment of Metabolic Syndrome
Catalysis SL n=100

Full NASH/NAFLD Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only